Physician profile
David Abellard
NPI 1083698401
$634.26
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $162 · 2021: $180 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.97 | 2021-2022 | |
| Abbott Laboratories | $84.74 | 2019-2021 | |
| Coloplast Corp | $44.44 | 2020 | |
| Abbvie INC. | $43.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.53 | 2019 | |
| Glaxosmithkline, LLC. | $28.56 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $24.81 | 2022 | |
| Amarin Pharma, INC. | $20.11 | 2019 | |
| Pfizer INC. | $18.26 | 2021 | |
| Lilly USA, LLC | $15.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.38 | 2022 | |
| Esperion Therapeutics, INC. | $13.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Abellard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.